Drug-induced liver injury with an autoimmune phenotype following anti-TNF therapy - Presentation of cases and review of literature;Medikamentöse Schädigung der Leber mit autoimmunem Phänotyp durch TNF-Blockade - Fallvorstellung und Review der Literatur 1

Zeitschrift fur Gastroenterologie

Volumn 52, Issue 1, 2014, Pages 58-63

  Rosner S ^a   Schad, A ^a   Kittner, J ^a   Rahman, F ^a   Worns M A ^a   Schuchmann, M ^a   Galle, P R ^a   Schattenberg, J M ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

anti TNF therapy; drug induced autoimmune hepatitis (DIH); drug induced liver injury (DILI); liver

Indexed keywords

TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; CASE REPORT; HISTOPATHOLOGY; HUMAN; LIVER FUNCTION TEST; PHENOTYPE; PSORIASIS; TOXIC HEPATITIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; AUTOIMMUNE DISEASES; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84892620447     PISSN: 00442771     EISSN: 14397803     Source Type: Journal    
DOI: 10.1055/s-0033-1356224     Document Type: Article

References (23)

1. Van Hauwermeiren F., Vandenbroucke R. E., Libert C. Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1. Cytokine & growth factor reviews: 2011; 22 311 319
2. Efe C. Drug induced autoimmune hepatitis and TNF-alpha blocking agents: is there a real relationship? Autoimmunity reviews: 2013; 12 337 339
3. Ghabril M., Bonkovsky H. L., Kum C. et al. Liver injury from tumor necrosis factor-alpha antagonists: analysis of thirty-four cases. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association: 2013; 11 558 564 e553
4. Colina F., Molero A., Casis B. et al. Infliximab-Related Hepatitis: A Case Study and Literature Review. Digestive diseases and sciences. 2013; 10.1007/s10620-013-2698-6
5. Weiler-Normann C., Schramm C. Drug induced liver injury and its relationship to autoimmune hepatitis. Journal of hepatology: 2011; 55 747 749
6. Hennes E. M., Zeniya M., Czaja A. J. et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology: 2008; 48 169 176 (Pubitemid 351975541)
7. Hadem J., Tacke F., Bruns T. et al. Etiologies and outcomes of acute liver failure in Germany. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association: 2012; 10 664 669 e662
8. Bjornsson E., Talwalkar J., Treeprasertsuk S. et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology: 2010; 51 2040 2048
9. Ramos-Casals M., Roberto Perez A., Diaz-Lagares C. et al. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmunity reviews: 2010; 9 188 193
10. Grasland A., Sterpu R., Boussoukaya S. et al. Autoimmune hepatitis induced by adalimumab with successful switch to abatacept. European journal of clinical pharmacology: 2012; 68 895 898
11. Tobon G. J., Canas C., Jaller J. J. et al. Serious liver disease induced by infliximab. Clinical rheumatology: 2007; 26 578 581 (Pubitemid 46359303)
12. Hagel S., Bruns T., Theis B. et al. Subacute liver failure induced by adalimumab. International journal of clinical pharmacology and therapeutics: 2011; 49 38 40
13. Becker H., Willeke P., Domschke W. et al. Etanercept tolerance in a patient with previous infliximab-induced hepatitis. Clinical rheumatology: 2008; 27 1597 1598
14. Weiler-Normann C., Schramm C., Quaas A. et al. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. Journal of hepatology: 2013; 58 529 534
15. Herkel J., Heidrich B., Nieraad N. et al. Fine specificity of autoantibodies to soluble liver antigen and liver/pancreas. Hepatology: 2002; 35 403 408 (Pubitemid 34106381)
16. Maini R., St Clair E. W., Breedveld F. et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet: 1999; 354 1932 1939
17. Charles P. J., Smeenk R. J., De Jong J. et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis and rheumatism: 2000; 43 2383 2390
18. Eriksson C., Engstrand S., Sundqvist K. G. et al. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Annals of the rheumatic diseases: 2005; 64 403 407 (Pubitemid 40283050)
19. Schattenberg J. M., Czaja M. J. TNF/TNF receptors. In: Dufour J. F., Clavien P. A. Hrsg. Signaling Pathways in Liver Disease. Heidelberg Springer: 2009; 161 179
20. Via C. S., Shustov A., Rus V. et al. In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. JÂ Immunol: 2001; 167 6821 6826 (Pubitemid 33144173)
21. Harada K., Akai Y., Koyama S. et al. A case of autoimmune hepatitis exacerbated by the administration of etanercept in the patient with rheumatoid arthritis. Clinical rheumatology: 2008; 27 1063 1066
22. Ganguly D., Haak S., Sisirak V. et al. The role of dendritic cells in autoimmunity. Nature reviews Immunology: 2013; 10.1038/nri3477
23. Manns M. P., Woynarowski M., Kreisel W. et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology: 2010; 139 1198 1206